Research Divisions

Tumour Immunology

Group LeaderLocation and ContactMembersHistory of the GroupLines of ResearchNotable PublicationsProjectsPhD ThesesClinical TrialsPatents and TrademarksNews

Professor Segundo González Rodríguez

Professor of Immunology at the Universidad de Oviedo.

Segundo González Rodríguez graduated in Medicine and Surgery at the Universidad de Oviedo in 1990, completed his specialist training in Immunology (through the Medical Residency Programme) at the Hospital Universitario Central de Asturias (HUCA) in 1995 and obtained his PhD in Medicine in 1996. He completed postdoctoral fellowships in HUCA’s Immunology Department from 1996 to 1997 and in the Clinical Research Division of the Fred Hutchinson Cancer Research Center’s Spies Lab (Seattle, US) in 2005.

He has lectured in immunology at the Universidad de Oviedo since 1997, where he has been Professor of Immunology since 2013. He has supervised 31 student research projects, including nine PhD theses, Diplomas of Advanced Studies, and Bachelor’s and Master’s dissertations.

He is editor of an immunology textbook, which has been the bestselling Spanish-language book on immunology in Spain and Latin America for many years.

He is currently Head of the Tumour Immunology research group at the Instituto Universitario Oncológico del Principado de Asturias (IUOPA). He has participated in 20 competitively-funded research projects and has entered into a large number of contracts as principal investigator with a range of national and international pharmaceutical companies.

He has completed 18 years of research and produced 129 publications, of which over 40 articles have been published in first decile or quartile journals, and has an H-factor of 40.

4ª planta, Facultad de Medicina

Julián Clavería s/n

33006 Oviedo, Spain.

NamePosition
Alejandro López SotoFull-time postdoctoral researcher on a project funded by Boehringer Inhelheim through the Fundación Universidad de Oviedo.
Ana Pilar González RodríguezSpecialist Health Professional (FEA) in the Haematology Department, Hospital Universitario Central de Asturias (HUCA). Associate Lecturer in Haematology at the Universidad de Oviedo. Lecturer in Medical and Surgical Pathology at the Escuela Universitaria de Enfermería de Gijón (University Nursing School of Gijón).
Ángel Ramírez PayerSection Head in the Haematology Department, HUCA.
María Esther González GarcíaFEA in the Haematology Department, Hospital Cabueñes, Gijón. Lecturer at the Escuela Universitaria de Enfermería de Gijón.
Christian Sordo BahamondePhD Researcher with the Fundación Universidad de Oviedo, funded by Boehringer Ingelheim, Austria.
Mónica Alvarez VillaShe is currently a PhD student in the Tumour Immunology research group.
Seila Lorenzo HerreroPhD Researcher. Severo Ochoa grant/contract from FICYT (Foundation for the Promotion of Applied Scientific Research and Technology in Asturias).
Juan Luis Fernández MartínezTenured Lecturer in Applied Mathematics, Universidad de Oviedo.
Zulima Fernández MuñizTenured Lecturer in Applied Mathematics, Universidad de Oviedo.
Enrique de Andrés GalianaAssistant Lecturer. Computer Science and Artificial Intelligence, Universidad de Oviedo.
Manuel Zamora ClementeComputer Science and Artificial Intelligence, Universidad de Oviedo.

 

Segundo González Rodríguez and Alejandro López Soto founded the Tumour Immunology group within the Instituto Universitario Oncológico del Principado de Asturias (IUOPA) in 2004. The group’s first objective was to study the immune response to cancer and immunotherapy, particularly the role NK cells play in this response. Our group initially focused on exploring the molecular and cellular mechanisms involved in the immune response to cancer.

It then expanded its objectives to include research on the role of the immune response in haematological and other types of cancer. Since then, several clinical research groups from the Haematological Departments of the Hospital Universitario Central de Asturias and Hospital Cabueñes have been incorporated into the group, such as those led by Drs Ana González, Ángel Payer and Esther Gonzalez.

  • Studying the immune response to cancer and the immune evasion mechanisms developed by cancer cells.
  • Characterising the mechanisms used by NK cells to eliminate cancer cells.
  • Developing new immunotherapeutic strategies for cancer treatment.
  • Studying the immunological bases of autoimmunity.
  • AUTHORS: Huergo-Zapico L, Gonzalez-Rodriguez AP, Contesti J, Lopez-Soto A, Fernández-Guizán A, Acebes-Huerta A, de los Toyos JR, López-Larrea C, Groh V, Spies T, Segundo Gonzalez.
    TITLE: Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: Association with soluble MICA shedding.
    Cancer Immunology Immunotherapy. 2012; 61(8):1201-10.
    Q1. IF: 4.846
  • AUTHORS: Alejandro López-Soto, Leticia Huergo-Zapico, José Antonio Galván, Luis Rodrigo, Antonio García de Herreros, Aurora Astudillo, Segundo González.
    TITLE: Epithelial-to-mesenchymal transition stimulates anti-tumor response mediated by NKG2D receptor.
    Journal of Immunology 2013, 190: 4408-4419
    Q1, IF 5.362
  • AUTHORS: Garrido P, J Moran, Alonso A, Segundo Gonzalez, Gonzalez C.
    TITLE: 17ß-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells.
    Endocrinology. 2013154(6):1979-89.
    Q1. IF: 4.159
  • AUTHORS: López-Soto A, Huergo Zapico L, Acebes-Huerta A, Rodrigo L, Gonzalez Segundo.
    TITLE: Regulation of NKG2D signaling during the epithelial-to-mesenchymal transition.
    Oncoimmunology 2013 Sep 1; 2(9):e25820.
    D1. IF: 7.644
  • AUTHORS: Alejandro López-Soto, Leticia Huergo-Zapico, Andrea Acebes-Huerta, Mónica Alvarez-Villa, Segundo Gonzalez.
    TITLE: NKG2D signaling in cancer immunosurveillance.
    International Journal of Cancer 2014 Feb 8.
    Q1. IF: 5.5310
  • AUTHORS: Leticia Huergo-Zapico, Andrea Acebes-Huerta, Ana Pilar Gonzalez-Rodriguez, Juan Contesti, Esther Gonzalez-García, Angel R Payer, Monica Villa-Alvarez, Azahara Fernández-Guizán, Alejandro López-Soto, Segundo Gonzalez.
    TITLE: Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease.
    PlosOne 2014 Oct 6;9(10):e108326.
    Q1. IF: 3.057
  • AUTHORS: Andrea Acebes-Huerta, Seila Lorenzo, Alicia R. Folgueras, Leticia Huergo-Zapico, Carlos Lopez-Larrea, Alejandro López-Soto, Segundo Gonzalez.
    TITLE: Hyperploidy stimulates an anti-tumor NK cell response mediated by NKG2D and DNAM-1.
    Oncoimmunology 2015 Aug 12;5(2):e1074378.
    D1. IF: 7.644
  • AUTHORS: Leticia Huergo Zapico, Andrea Acebes-Huerta, Alejandro López-Soto, Monica Villa-Alvarez, Ana P Gonzalez-Rodriguez, Segundo Gonzalez.
    TITLE: Molecular bases for the regulation of NKG2D ligands in cancer.
    Frontiers in Immunology, 2014 2014 Mar 21;5:106.
    Q1. IF: 5.695
  • AUTHORS: Azahara Fernandez-Guizán, Alejandro López-Soto, Andrea Acebes-Huerta, Leticia Huergo-Zapico, Monica Villa-Alvarez, Luz-Elena Núñez, Francisco Morís, Segundo Gonzalez.
    TITLE: Pleiotropic anti-angiogenic and anti-oncogenic activities of the novel mithralog demycarosyl-3D-ß-D-digitoxosyl-mithramycin SK (EC-8042)
    Plos One 2015 Nov 4;10(11):e0140786
    Q1. IF: 3.057
  • AUTHORS: Julio Delgado; Itziar Salaverria; Tycho Baumann; Alejandra Martínez Trillos; Eriong Lee; Laura Jiménez; Alba Navarro; Cristina Royo; Rodrigo Santacruz; Cristina López; Angel R Payer; Enrique Colado; Marcos González;Lluís Armengol; Dolors Colomer; Magda Pinyol; Neus Villamor; Marta Aymerich; Ana Carrió; Dolors Costa; Guillem Clot; Eva Giné; Armando López Guillermo; Elías Campo; Sílvia Beà.
    TITLE: Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.
    Haematologica. 11, pp. e231. (Italy): 11/2014. ISSN 1592-8721
    Q1. IF: 6.671
  • AUTHORS: Enrique J deAndrés-Galiana, Juan Luis Fernández-Martínez Oscar Luaces, Juan Jose del Coz, PD Leticia Huergo-Zapico, Andrea Acebes-Huerta, Segundo Gonzalez, Ana Pilar González-Rodríguez
    TITLE: Analysis of clinical prognostic variables for Chronic Lymphocytic Leukemia decision-making problems.
    Journal of Biomedical Informatics 2016; 60:342-351.
    Q1. IF: 2.447
  • AUTHORS: Alejandro López-Soto, Jose Bravo-San Pedro, Guido Kroemer, Lorenzo Galluzzi, Segundo Gonzalez.
    TITLE: Involvement of autophagy in NK cell development and function.
    Autophagy 2017 Mar 4;13(3):633-636.
    D1. IF: 9.108
  • AUTHORS: Alicia R. Folgueras, Segundo Gonzalez and Alejandro López-Soto.
    TITLE: NKG2D signaling: the immune subversive side of HDAC3.
    Trends in Immunology 2017 TREIMM 1352
    D1. IF: 11.433
  • AUTHORS: Qing Chen; Adrienne Boire; Xin Jin; Manuel Valiente; Ekrem Emrah Er; Alejandro Lopez Soto; Leni S Jacob; Ruzeen Patwa; Hardik Shah; Ke Xu; Justin R Cross; Joan Massagué.
    TITLE: Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer.
    Nature. 533 – 7604: 493 – 501.
    D1. IF: 38.138.
  • AUTHORS: Alejandro López-Soto, Seila Lorenzo Herrero, Segundo Gonzalez.
    TITLE: Biallelic IRF8 mutations causing NK cell deficiency.
    Trends in Molecular Medicine 2017 Mar;23(3):195-197.
    D1. IF: 9.292
  • AUTHORS: Lorenzo Galluzzi; Alejandro López Soto; Sharad Kumar; Guido Kroemer.
    TITLE: Caspases Connect Cell-Death Signaling to Organismal Homeostasis.
    Immunity. 44 – 2:221– 252.
    D1. IF: 24.082
  • AUTHORS: Alejandro López-Soto, Segundo Gonzalez, Mark J. Smyth, and Lorenzo Galluzzi.
    TITLE: Control of metastasis by NK cells.
    Cancer cell 2017 Aug 14;32(2):135-154.
    D1. IF: 27.407
  • AUTHORS: Huergo Zapico L, Parodi M, Cantoni C, Lavarello C, Fernández-Martínez J, Petretto A, DeAndrés-Galiana E, Balsamo M, López-Soto A, Pietra G, Bugatti M, Munari E, Marconi M, Mingari MC, Vermi W, Moretta L, Segundo Gonzalez, Vitale M.
    TITLE: NK cells edit melanoma cells by inducing phenotype switching, EMT, and changes in proteomic profiles related to tumor progression.
    Cancer Research 2018.
    D1. IF: 9.130
  • AUTHORS: Mónica Villa-Álvarez, Ana P. Gonzalez-Rodriguez, Alejandro López-Soto, Angel R. Payer, Esther Gonzalez-Garcia, Leticia Huergo-Zapico; Segundo Gonzalez.
    TITLE: Ig-like transcript 2 (ILT2) suppresses T cell function in Chronic Lymphocytic Leukemia.
    Oncoimmunology 2017;6(10):e1353856.
    D1. IF: 7.644.
  • AUTHORS: A. Lopez-Soto, Segundo González, C. Lopez-Larrea, G Kroemer.
    TITLE: Immunosurveillance of malignant cells with complex karyotypes.
    Trends in Cell Biology, 2017; 27: 890-94.
    D1. IF: 15.333.
Principal InvestigatorTitleFunding BodyDurationAmount
Segundo González RodríguezDetermining new mithramycin analogues’ mechanism of action and their synergism with other chemotherapeuticsFICYT. PC10-31. Participating company: Entrechem2010 – 2012€72,179.97
Segundo González RodríguezInducing the antitumour activity of NK and NKT-line cells: implications for cancer immunotherapy.Health Research Fund (FIS) PI12/012802013 – 2017€102,850.97
Segundo González RodríguezInducing the antitumour activity of NK and NKT-line cells: implications for cancer immunotherapy.FICYT COF11-241/1/201231/12/2012€24,000
Segundo González RodríguezThe oncoimmunological activity of kinase inhibitor EC-70124.Instituto de Desarrollo Económico del Principado de Asturias (Economic Development Agency of the Principality of Asturias ). Co-funded by Entrechem SL. Reference Number: B7407915301/01/201631/12/2016€25,000
Segundo González RodríguezAssessment of the effect of CDK8 inhibition on NK cells in chronic lymphocytic leukaemia.Boehringer Inhelheim, Vienna, Austria. FUO-107-162016 – 2017€50,000
Segundo González RodríguezThe cooperative effect of lenalidomide, PD-L1 and ILT-2 blockade in multiple myeloma.Celgene Europe2016 – 2017€78,000
Segundo González RodríguezThe impact of the gene signature on immune system activity and immunotherapy in chronic lymphocytic leukaemia.Instituto de Salud Carlos III; PI16/014852016 – 2018€98,615
Segundo González RodríguezInduction of immunogenic cell death and activation of the immune system by the EC-70124 compound.Entrechem. FUO-EM-037-1412/02/201430/06/2014€7,115.92 + VAT
Segundo González RodríguezEffect of LAG-3 blockade in the antileukaemic activity of NK and T cells in chronic lymphocytic leukaemia.Bristol Myers Squibb Co, Lawrenceville, NJ, USA01/06/201601/06/2018Material support for the project
SupervisorsTitlePhD StudentYearProgramme
Segundo González RodríguezModulation of inflammatory and neoplastic processes in the colon by functional foodstuffs in murine animal modelsLeticia Huergo Zapico2014Doctoral Programme in Cancer Research with a Quality Citation
Thesis with European honours

Outstanding PhD award

Segundo González RodríguezCarlos López LarreaInfluence of the non-classical histocompatibility MICA and MICB molecules on the clinical heterogeneity of coeliac disease.Antonio López Vázquez2015Functional Biology Doctoral Programme, Universidad de Oviedo.
Segundo González RodríguezAlejandro López SotoDevelopment of antitumour immune response activation strategies mediated by NK cells.Andrea Acebes Huerta2015Functional Biology Doctoral Programme, Universidad de Oviedo
Thesis with European honours

Real Academia de Medicina del Principado de Asturias (Royal Academy of Medicine of Asturias) Prize for the Best PhD Thesis submitted to the Universidad de Oviedo in the Medicine section 2016

  • Title: RELMC-NOVA Study: Prospective Observational Study to Evaluate the Precocity, Stability and Depth of the Molecular Response in Recently Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients (CP-CML) Treated with Inhibitors of Tyrosine Kinase Activity (ITK) as a First-Line Treatment in Clinical Practice.
    Code: FMS-ITK-2016-01
    PI: Angel Ramírez Payer.
    Sponsor: Fundacion Miguel Servet. GELMC (Spanish Chronic Myeloid Leukaemia Group)
    Year: 2017
  • Title: A Phase 1/2, Open Label, Multicentre Clinical Trial to Evaluate the Role of Nivolumab in Combination with Pomalidomide and Dexamethasone and of Nivolumab in Combination with Pomalidomide, Dexamethasone and Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma Patients.
    EudraCT No 2015‐005608‐28
    Collaborating Investigator : Angel Ramírez Payer.
    Sponsor: Fundación PETHEMA (Programme for the Study and Treatment of Haematological Malignancies)
    Year: 2017
  • Title: GEM NIVOPOMDEX: Open-label, Multicentre Phase 1 Clinical Trial to Evaluate the Role of Nivolumab in Combination with Pomalidomide and Dexamethasone and of Nivolumab in Combination with Pomalidomide, Dexamethasone and Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma Patients.
    Organisation: PETHEMA
    Principal Investigator: Ana Pilar Gonzalez
    Start Date: April 2017-
    Duration: 66 months
  • Title: INTERNATIONAL CANCER GENOME CONSORTIUM: CHRONIC LYMPHOCYTIC LEUKAEMIA
    Organisation Conducting the Trial: Hospital Universitario Central de Asturias
    Type of Organisation: Health Organisation
    Principal Investigators (PI, Co-PI,etc.): Dr Elías Campo, Carlos López Otín
    Collaborating Investigator: Ángel Ramírez Payer
    Started in: 2011
  • Title: Phase 3B, Randomised Trial of Lenalidomide Versus Placebo Maintenance Therapy Following Melphalan, Prednisone and Velcade Induction Therapy In Newly Diagnosed Multiple Myeloma.
    Code: CC-5013-MM-026.
    Sponsor: Celgene
    Role: Scientific Coordinator: Ángel Ramírez Payer
    Started in: 2015
  • Title: Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination with Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients with Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to Receive ASCT.
    Protocol Number: IBDCL-2015. EudraCT No: 2015-005390-21.
    Sponsor: GELTAMO (Spanish Lymphoma and Bone Marrow Transplantation Group)
    Level of Participation: Scientific Coordinator: Ángel Ramírez Payer
    Started in: 2015
  • Title: A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas in the Spanish Population.
    Code: TAK-HEM-2015-01.
    Sponsor: Takeda
    Role: Investigator: Ángel Ramírez Payer
    Started in: 2015
  • Title: A Randomised, Open-Label, National Multicentre, Phase III Trial Studying Maintenance Treatment with Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 after Autologous Haematopoietic Stem Cell Transplant in Patients with Newly-Diagnosed, Symptomatic Multiple Myeloma.
    GEM2014MAIN. Eudra CT No 2014-000554-10.
    Sponsor: Fundación PETHEMA.
    Participating Organisation: HUCA
    Investigators: Ana Pilar González Rodríguez and Ángel Ramirez Payer
    Started in: 2015
  • Title: LR-ESHAP: National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation
    Sponsor: GELTAMO
    Role: Scientific Coordinator
    Investigators: Ana Pilar González Rodríguez and Ángel Ramirez Payer
    Started in: 2015
  • Title: Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukaemia with Stable Complete Molecular Response.
    Code: DASFREE, CA180406
    Sponsor: BMS
    Role: Scientific Coordinator: Ángel Ramírez Payer
    Started in: 2015
  • Title: A Phase 3, Multicentre, Open-label, Randomised Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukaemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy.
    EudraCT Number: 2014-001233-89
    Role: Investigator: Ángel Ramírez Payer
    Started in: 2014
  • Title: Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) Plus Bendamustine Treatment in Patients With Refractory Or Relapsed Chronic Lymphocytic Leukaemia.
    Sponsor: Roche Farma
    Role: Scientific Coordinator
    Participating Organisation: Hospital Universitario Central de Asturias
    Investigators: Ana Pilar González Rodríguez and Ángel Ramirez Payer
    Started in: 2014
  • Title: Phase II Clinical Trial to Evaluate the Combination of Lenalidomide with R-GDP (Rituximab, Gemcitabine, Dexamethasone and Cisplatin) in Patients Diagnosed with Refractory Diffuse Large B-cell Lymphoma Not Candidates for High-Dose Chemotherapy and Haematopoietic Progenitor Cell Transplantation.
    EudraCT No: 2014-001620-29
    Sponsor: GOTEL (Spanish Group for the Treatment and Study of Lymphoma)
    Role: Investigator: Ángel Ramírez Payer
    Started in: 2014
  • Title: Observational, Post-Authorisation Registry to Evaluate the Clinical Impact of Starting Antitumour Salvage Therapy in Multiple Myeloma Patients in Asymptomatic Biological Relapse Versus Starting Treatment in Symptomatic Relapse.
    EPA-MMBR CEL-MIE 2012-0 Study
    Sponsor: Celgene.
    Participating Organisation: Hospital Universitario Central de Asturias
    Investigators: Ana Pilar González Rodríguez and Ángel Ramirez Payer
    Started in: 2014
  • Title: Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Haematological Malignancies.
    CEL-GAH-0211-01. Collaborating Investigator
    Sponsor: Celgene
    Role: Investigator: Ángel Ramírez Payer
    Started in: 2014
  • Title: Post Authorisation, Multicentre Study With a Non-Prospective-Monitoring Design. Study of the Applicability of ITK Treatment for Chronic Myeloid Leukaemia Patients Aged ≥ 70 Years.
    (EPA-OD)
    Sponsor: GELMC.
    Role: Scientific Coordinator
    Started in: 2013
  • Title: Registry of the Use of Tyrosine Kinase Inhibitors as Third-Line Treatment in Chronic Myeloid Leukaemia Patients.
    Sponsor: GELMC.
    Role: Scientific Coordinator: Ángel Ramírez Payer
    Started in: 2013
  • Title: Phase 3 Multi-Centre Randomised Study to Compare Efficacy and Safety of Romidepsin-CHOP (Ro-CHOP) versus CHOP in Subjects with Previously Untreated Peripheral T-Cell Lymphoma.
    Code: 2012-001580-68.
    Sponsor: Celgene
    Role: Investigator: Ángel Ramírez Payer
    Started in: 2012
  • Title: A Prospective, Randomised, Open Label Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients with Philadelphia Chromosome-Positive CML After Two Different Durations of Consolidation Treatment with Nilotinib 300mg BID.
    PROTOCOL CODE: CAMN107AIC05 and EUDRACT No: 2012-005124-15.
    Sponsor: Novartis.
    Role: Scientific Coordinator: Ángel Ramírez Payer
    Started in: 2012
  • Title: Registry of Myeloid Leukaemia Patients with a High Probability of Reaching Complete Molecular Response.
    Code: FMS-LMC-2012-01-IP
    Sponsor: PETHEMA
    Role: Investigator: Ángel Ramírez Payer
    Started in: 2012
  • Title: A Phase II Multicentre Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) plus High-Dose Therapy with Melphalan-200 and Autologous Stem Cell Transplantation, Followed by Consolidation with KRd, and Maintenance with Lenalidomide and Dexamethasone in Patients with High Risk Smouldering Multiple Myeloma (SMM) Under 65 Years.
    GEM-CESAR 2014-002948-40
    Type of Project: Clinical
    Type of Participation: Ana Pilar González Rodríguez
    Organisation Conducting the Trial: PETHEMA
    Type of Organisation: Foundation
    Start Date: 01/02/2016
  • Title: Post-Authorisation, Non-Interventionist Registry of Remitting and Relapsing Multiple Myeloma Patients Treated with Pomalidomide who have Received at Least Two Prior Treatments, Including Lenalidomide and Bortezomib, and who have Undergone Progression During the Last Treatment.
    Observational Study: EPA-LA.
    Tender Reference No: CC-4047-MM-015
    Type of Participation: Team Member: Ana Pilar González Rodríguez
    Funding Body: Celgene Corporation
    Type of Organisation: Company
    Start Date: 01/01/2015
  • Title: LR-ESHAP: National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation
    Type of Participation: Principal investigator
    Principal Investigator: Ana Pilar González Rodríguez
    Funding Body: GELTAMO
    Type of Organisation: Foundation
    Investigators: Ana Pilar González Rodríguez and Ángel Ramirez Payer
    Start Date: 01/01/2015
  • Title: Phase I-II Clinical Trial for the Evaluation of the Role of Brentuximab Vedotin plus Etoposide, Solumoderin, High Dose ARA-C and Cis-Platin in Transplant and Post-Transplant Management for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma.
    Name of the Tender: BRESHAP-GELTAMO. LH 2013
    Tender Reference No: EudraCT No: 2014-000835-17
    Funding Body: GELTAMO
    Type of Organisation: Foundation
    Type of Participation: Principal investigator
    Principal Investigator: Ana Pilar González Rodríguez
    Investigators: Ana Pilar González Rodríguez and Ángel Ramirez Payer
    Start Date: 02/12/2014
  • Title: Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals’ Herpes Zoster Vaccine GSK1437173A. A Phase III, Randomised, Observer-Blind, Placebo-Controlled, Multicentre, Clinical Trial to Assess the Prophylactic Efficacy, Safety, and Immunogenicity of GSK Biologicals’ Herpes Zoster gE/AS01B Candidate Vaccine when Administered Intramuscularly on a Two-Dose Schedule to Adult Autologous Haematopoietic Stem Cell Transplant (HCT) Recipients with Protocol Code 115523 (Zoster-002).
    Funding Body: GlaxoSmithKline Biologicals
    Type of Organisation: Company
    Type of Participation: Principal investigator
    Principal Investigator: Ana Pilar González Rodríguez
    Start Date: 20/11/2014 Duration: Two years
  • Title: Post-Authorisation Observational Registry to Assess the Clinical Impact of Initiating Anti-Tumour Rescue Therapy in Patients With Multiple Myeloma (MM) in Asymptomatic Biological Relapse Compared to Initiating Treatment at the Time of Symptomatic Relapse (EPA-MMBR Study).
    Tender Reference No: CEL-MIE 2012-02
    Funding Body: Celgene Corporation
    Type of Organisation: Company
    Type of Participation: Principal investigator
    Principal Investigator: Ana Pilar González Rodríguez
    Investigators: Ana Pilar González Rodríguez and Ángel Ramirez Payer
    Start Date: 10/2014
  • Title: Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) Plus Bendamustine Treatment in Patients With Refractory Or Relapsed Chronic Lymphocytic Leukaemia.
    Funding Body: Roche Farma, S.A.
    Type of Organisation: Company
    Type of Participation: Team member
    Investigators: Ana Pilar González Rodríguez and Ángel Ramirez Payer
    Start Date: 01/04/2014
  • Title: Open-Label National Phase II, Multicentre Study of Bendamustine, Bortezomib and Prednisone in Patients with Newly Diagnosed Multiple Myeloma.
    Organisation Conducting the Trial: PETHEMA
    Type of Organisation: Foundation
    Type of Participation: Team Member: Ana Pilar González Rodríguez
    Start Date: 01/01/2013
    Duration: One year
  • Title: Retrospective Study on the Efficacy and Prognostic Factors of the Last Decade’s Protocols of the Asturian Group on Lymphomas in Hodgkin’s Disease. Study 6/2013
    Funding Body: Grupo Asturiano de Linfomas (Asturian Lymphoma Group).
    Type of Organisation: Associations and Groups
    Type of Participation: Principal investigator
    Principal Investigator: Ana Pilar González Rodríguez
    Start Date: 1/2013
  • Title: National, Multicentre, Open-Label, Randomised Study of Induction Therapy with Bortezomib/Lenalidomide/Dexamethasone (VRD-GEM), Followed by High-Dose Chemotherapy with Melphalan-200 (MEL-200) Versus Busulfan-Melphalan (BUMEL) and Consolidation with VRD-GEM for Newly-Diagnosed Symptomatic Multiple Myeloma Patients Under 65 Years.
    Organisation Conducting the Trial: PETHEMA
    Type of Organisation: Foundation
    Type of Participation: Principal investigator
    Principal Investigator: Ana Pilar González Rodríguez
    Started In: 2013
    Duration: Five years
  • Title: Bendamustine, Cytarabine, Etoposide and Melphalan as Conditioning for Autologous Haematopoietic Stem Cell Transplant in Patients With Aggressive Lymphoma.
    Tender Reference No: Benda-EAM2010-01.
    Funding Body: GELTAMO
    Type of Participation: Principal investigator
    Type of Organisation: Foundation
    Principal Investigator: Ana Pilar González Rodríguez
    Start Date: 01/06/2011
    Duration: One year
  • Title: Advance Therapy for Invasive Aspergillosis in High-Risk Oncohaematological Patients Through the Use of PCR for Early Detection of Aspergillus.
    Tender Reference No: PCRAGA
    Funding Body: Grupo Español de Trasplante Hematopoyético y Terapia Celular (Spanish Haematopoietic Transplantation and Cell Therapy Group)
    Type of Organisation: Associations and Groups
    Type of Project: Clinical Type of Participation: Team Member: Ana Pilar González Rodríguez
    Start Date: 15/02/2011
  • Title: Activity and Safety Study of Lenalidomide and Rituximab as Non-Chemotherapy Based Therapy on Chronic Lymphocytic Leukaemia (LLC-LENAR-08).
    Principal Investigator: José Francisco Tomás; MD Anderson International Spain. Sponsor: MD Anderson International Spain SA
    Collaborator: Celgene Corporation
    ClinicalTrials.gov Identifier: NCT01185262
    Study First Received: 17 December 2009
    Role of the Immunology Unit: Study of patients’ immune response.
    Investigators: Segundo Gonzalez, Ana P. Gonzalez Rodríguez, Esther Gonzalez
    Incorporation Date: 2011
  • Title: CEL-MIE-2012-01
    Type of Study: Post-approval Study (PAS) – Prospective Follow-up
    Sponsor: Celgene
    PI: Esther González
    Year: 2017
  • Title: CEL-MIE-2012-02
    Type of Study: PAS-MMBR
    Sponsor: Celgene
    PI: Esther González
    Year: 2017
  • Title: GEM-2012-MENOS65
    Type of Study: Clinical Trial
    PI: Esther González
    Year: 2017
  • Title: GEM-2012-MENOS65
    Type of Study: Clinical Trial
    PI: Esther González
    Year: 2017
  • Title: GEM2014MAIN
    Type of Study: Clinical Trial
    PI: Esther González
    Year: 2017
  • Title: GEM-CLARIDEX
    Type of Study: Clinical Trial
    PI: Esther González
    Year: 2017
  • Title: MEDI4736-MM-003
    Type of Study: Clinical Trial
    PI: Esther González
    Year: 2017
  • Title: MO28107 LLC
    Type of Study: Clinical Trial
    PI: Esther González
    Year: 2017
  • Title: ML29167LNH
    Type of Study: Clinical Trial
    PI: Esther González
    Year: 2017
  • Title: GELTAMO-MAN2
    Type of Study: Clinical Trial
    Collaborating Investigator: Esther González
    Year: 2017
  • Title: RV-CLL-CGLLSG-0725
    Type of Study: Clinical Trial
    Collaborating Investigator: Esther González
    Year: 2017
  • Title: Pharmacyclics PCYC-1141-CA
    Type of Study: Clinical Trial
    Collaborating Investigator: Esther González
    Year: 2017
  • Title: GEM-KYCYDEX Trial. Adds a renal function sub-study for the whole of Spain that is already approved by AMGEM.
    Type of Study: Clinical Trial
    Principal Investigator: Esther González
    Year: 2017
  • Title: USEFULNESS OF NEW RENAL FUNCTION MARKERS IN RELAPSED OR REFRACTORY MYELOMA PATIENTS IN TREATMENT WITH CARFILZOMIB. Study associated with the clinical trial with code GEM-KyCyDex (Appendix J)
    Type of Study: GEM-KYCYDEX SUB-STUDY
    Principal Investigator: Esther González
    Year: 2017
  • Title: CharisMMa
    Type of Study: PAS
    Collaborating Investigator: Esther González
    Year: 2017
  • Title: Myeloma Monitoring Study (Estudio Mieloma Monitor)
    Type of Study: Registry
    Collaborating Investigator: Esther González
    Year: 2017